Navigation Links
Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
Date:12/15/2008

NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the exclusive rights to a new and promising tumor treatment using an RNAi based therapeutic technology for the potential use against a broad range of cancers.

This technology, which specifically targets a novel cancer biomarker, was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.

Frank Massino, CEO and Chairman of Senetek, commented, "We are extremely pleased that our relationship with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences has resulted in another important addition to our technology portfolio. We look forward to the opportunities that lie ahead with this novel advancement in RNAi therapy."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

     Company Contact:
     William O'Kelly
     Senetek PLC
     1-707-226-3900, ext. 102

'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek Affirms Strong Financial Position
2. Senetek PLC Reports Second Quarter 2008 Financial Results
3. Senetek PLC Reports First Quarter 2008 Financial Results
4. Senetek PLC Announces Appointments of Key Personnel
5. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
6. Quantros Acquires MEDMARX(R) from United States Pharmacopeia (USP)
7. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
8. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
9. Vyta Corp Acquires 100% Ownership of BIOAGRA, LLC
10. Affitech Acquires Pharmexas Diabody Technology
11. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers ... with fingerprint recognition for secure access, voice recognition for hands-free communication, and facial ... are interacting with biometrics technology today. But if they asked Joey Pritikin, ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... has joined the company as an Expert Consultant. Mr. Clark was formerly ... and managing the development of small molecule monographs based on analytical methods. ...
(Date:4/27/2016)... ... , ... Global Stem Cells Group and the University of Santiago ... and development initiatives for potential stem cell protocol management for 2016 – 2020. ... began meeting to establish a working agenda and foster initiatives to promote stem cell ...
(Date:4/26/2016)... ... April 26, 2016 , ... ... Ardy Arianpour has joined the company as Chief Business Officer. Arianpour, a genomics ... genomic technologies to market, was most recently Chief Commercial Officer of Pathway Genomics. ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):